• Clearmind Medicine published three U.S. patent applications covering combinations of LSD, ketamine, ibogaine with N-acylethanolamines such as PEA.
• Applications target potential treatments for depression, PTSD, pain, substance use disorders, aiming for lower doses with maintained efficacy.
• Publications expand IP from its collaboration with NeuroThera Labs, integrating PEA technology into psychedelic-derived therapeutic programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230757PRIMZONEFULLFEED9832425) on September 23, 2026, and is solely responsible for the information contained therein.